WallStreetZenWallStreetZen

NYSE: HLN
Haleon PLC Stock

Overview
ForecastEarningsRevenueDividendOwnership
$10.22+0.06 (+0.59%)
Updated Apr 17, 2025
HLN Price
$10.22
Fair Value Price
N/A
Market Cap
$46.42B
52 Week Low
$8.12
52 Week High
$10.80
P/E
24.93x
P/B
2.21x
P/S
3.1x
PEG
2x
Dividend Yield
N/A
Revenue
$14.59B
Earnings
$1.80B
Gross Margin
60.7%
Operating Margin
19.4%
Profit Margin
12.8%
Debt to Equity
1.12
Operating Cash Flow
$3B
Beta
0.34
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine HLN's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

C
Value
C
Growth
C
Momentum
B
Sentiment
D
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Pharmaceutical

Industry Rating
B
HLN
Ranked#22 of 54

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Amneal Pharmaceuticals (AMRX)
$7.36A
Pacira Biosciences (PCRX)
$24.65A
Hutchmed (HCM)
$13.76A
View Top Pharmaceutical Stocks

Be the first to know about important HLN news, forecast changes, insider trades & much more!

HLN News

Overview

Due Diligence Score

–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HLN scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

HLN ($10.22) is trading above its intrinsic value of $4.00, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HLN is good value based on its earnings relative to its share price (24.93x), compared to the US market average (27.98x)
P/E vs Market Valuation
HLN is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more HLN due diligence checks available for Premium users.

Valuation

HLN price to earnings (PE)

For valuing profitable companies with steady earnings

Company
24.93x
Industry
20.48x
Market
27.98x
HLN is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
HLN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

HLN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.21x
Industry
1.99x
HLN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

HLN price to earnings growth (PEG)

For valuing profitable companies with growth potential

HLN is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

HLN's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
HLN's Earnings (EBIT) of $2.83B... subscribe to Premium to read more.
Interest Coverage Financials
HLN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$42.9B
Liabilities
$22.6B
Debt to equity
1.12
HLN's short-term liabilities ($7.55B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HLN's long-term liabilities ($15.95B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HLN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
HLN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
HLN's operating cash flow ($2.99B)... subscribe to Premium to read more.
Debt Coverage Financials

HLN vs Pharmaceutical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
HLNC$46.42B+0.59%24.93x2.21x
TAKC$46.64B+0.41%34.45x0.97x
ZTSC$66.57B+1.30%27.18x13.96x
TEVAC$15.48B+1.64%-9.41x2.88x
RDYC$11.40B+1.71%17.02x3.39x
View Top Pharmaceutical Stocks

Haleon Stock FAQ

What is Haleon's quote symbol?

(NYSE: HLN) Haleon trades on the NYSE under the ticker symbol HLN. Haleon stock quotes can also be displayed as NYSE: HLN.

If you're new to stock investing, here's how to buy Haleon stock.

What is the 52 week high and low for Haleon (NYSE: HLN)?

(NYSE: HLN) Haleon's 52-week high was $10.80, and its 52-week low was $8.12. It is currently -5.37% from its 52-week high and 25.86% from its 52-week low.

How much is Haleon stock worth today?

(NYSE: HLN) Haleon currently has 9,083,725,919 outstanding shares. With Haleon stock trading at $10.22 per share, the total value of Haleon stock (market capitalization) is $46.42B.

Haleon stock was originally listed at a price of $7.41 in Jul 22, 2022. If you had invested in Haleon stock at $7.41, your return over the last 2 years would have been 37.92%, for an annualized return of 17.44% (not including any dividends or dividend reinvestments).

How much is Haleon's stock price per share?

(NYSE: HLN) Haleon stock price per share is $10.22 today (as of Apr 17, 2025).

What is Haleon's Market Cap?

(NYSE: HLN) Haleon's market cap is $46.42B, as of Apr 21, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Haleon's market cap is calculated by multiplying HLN's current stock price of $10.22 by HLN's total outstanding shares of 9,083,725,919.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.